Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors
Protein kinases have essential responsibilities in controlling several cellular processes, and their abnormal regulation is strongly related to the development of cancer. The implementation of protein kinase inhibitors has significantly transformed cancer therapy by modifying treatment strategies. T...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/13/19/1656 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850283805788602368 |
|---|---|
| author | Mohammed Hawash |
| author_facet | Mohammed Hawash |
| author_sort | Mohammed Hawash |
| collection | DOAJ |
| description | Protein kinases have essential responsibilities in controlling several cellular processes, and their abnormal regulation is strongly related to the development of cancer. The implementation of protein kinase inhibitors has significantly transformed cancer therapy by modifying treatment strategies. These inhibitors have received substantial FDA clearance in recent decades. Protein kinases have emerged as primary objectives for therapeutic interventions, particularly in the context of cancer treatment. At present, 69 therapeutics have been approved by the FDA that target approximately 24 protein kinases, which are specifically prescribed for the treatment of neoplastic illnesses. These novel agents specifically inhibit certain protein kinases, such as receptor protein-tyrosine kinases, protein-serine/threonine kinases, dual-specificity kinases, nonreceptor protein-tyrosine kinases, and receptor protein-tyrosine kinases. This review presents a comprehensive overview of novel targets of kinase inhibitors, with a specific focus on cyclin-dependent kinases (CDKs) and epidermal growth factor receptor (EGFR). The majority of the reviewed studies commenced with an assessment of cancer cell lines and concluded with a comprehensive biological evaluation of individual kinase targets. The reviewed articles provide detailed information on the structural features of potent anticancer agents and their specific activity, which refers to their ability to selectively inhibit cancer-promoting kinases including CDKs and EGFR. Additionally, the latest FDA-approved anticancer agents targeting these enzymes were highlighted accordingly. |
| format | Article |
| id | doaj-art-2f2f8c30e69f4e41aa9a19534b9d4815 |
| institution | OA Journals |
| issn | 2073-4409 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj-art-2f2f8c30e69f4e41aa9a19534b9d48152025-08-20T01:47:42ZengMDPI AGCells2073-44092024-10-011319165610.3390/cells13191656Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR InhibitorsMohammed Hawash0Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus P.O. Box 7, PalestineProtein kinases have essential responsibilities in controlling several cellular processes, and their abnormal regulation is strongly related to the development of cancer. The implementation of protein kinase inhibitors has significantly transformed cancer therapy by modifying treatment strategies. These inhibitors have received substantial FDA clearance in recent decades. Protein kinases have emerged as primary objectives for therapeutic interventions, particularly in the context of cancer treatment. At present, 69 therapeutics have been approved by the FDA that target approximately 24 protein kinases, which are specifically prescribed for the treatment of neoplastic illnesses. These novel agents specifically inhibit certain protein kinases, such as receptor protein-tyrosine kinases, protein-serine/threonine kinases, dual-specificity kinases, nonreceptor protein-tyrosine kinases, and receptor protein-tyrosine kinases. This review presents a comprehensive overview of novel targets of kinase inhibitors, with a specific focus on cyclin-dependent kinases (CDKs) and epidermal growth factor receptor (EGFR). The majority of the reviewed studies commenced with an assessment of cancer cell lines and concluded with a comprehensive biological evaluation of individual kinase targets. The reviewed articles provide detailed information on the structural features of potent anticancer agents and their specific activity, which refers to their ability to selectively inhibit cancer-promoting kinases including CDKs and EGFR. Additionally, the latest FDA-approved anticancer agents targeting these enzymes were highlighted accordingly.https://www.mdpi.com/2073-4409/13/19/1656cancercell lineskinasesCDKsEGFRFDA |
| spellingShingle | Mohammed Hawash Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors Cells cancer cell lines kinases CDKs EGFR FDA |
| title | Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors |
| title_full | Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors |
| title_fullStr | Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors |
| title_full_unstemmed | Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors |
| title_short | Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors |
| title_sort | advances in cancer therapy a comprehensive review of cdk and egfr inhibitors |
| topic | cancer cell lines kinases CDKs EGFR FDA |
| url | https://www.mdpi.com/2073-4409/13/19/1656 |
| work_keys_str_mv | AT mohammedhawash advancesincancertherapyacomprehensivereviewofcdkandegfrinhibitors |